Basecamp Research, an AI-driven biotech company, has announced two major developments: a $60 million Series B funding round and a new collaboration with the Broad Institute of MIT and Harvard.
The London-based startup's funding round was led by Singular, with participation from S32 and industry figures including André Hoffmann, Vice-Chairman of Roche. Basecamp Research intends to use the funds to expand its data collection efforts and enhance its AI capabilities.
The company is partnering with Dr. David R. Liu's laboratory at the Broad Institute to explore new approaches to programmable genetic medicines. This research aims to advance potential treatments for various diseases.
Basecamp Research's CEO, Dr. Glen Gowers, explained the company's focus: "We're addressing the fundamental data gap that the entire biotech industry faces."
The startup reports that its foundational dataset contains 100 times more advanced biological systems than commonly used public databases. Basecamp Research also claims to have outperformed AlphaFold-2 in predicting complex protein structures.
To support its growth, Basecamp Research has hired Anupama Hoey as Chief Commercial Officer. Hoey brings over 20 years of leadership experience to the role.
This development represents a notable step in applying AI to biological research, with potential implications for drug discovery and genetic medicine advancements.